Kuehn Law Encourages Investors of Soleno Therapeutics, Inc. to Contact Law Firm

Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Soleno Therapeutics, Inc. (NASDAQ: SLNO ) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Soleno Therapeutics misrepresented or failed to disclose that: (a) Soleno's Phase 3 clinical trial program for DCCR, a potential treatment for PWS and hyperphagia, systematically downplayed, misrepresented, and/or concealed significant evidence of safety concerns associated with DCCR, including excess fluid retention observed in clinical trial participants; (b) as a result, DCCR's use for the treatment of hyperphagia in individuals with Prader-Willi syndrome ("PWS") posed materially greater safety risks than the Company and its executives had disclosed; and (c) consequently, DCCR had materially lower commercial viability and faced significant undisclosed risks following its commercial launch, including increased patient discontinuation, reduced patient adoption, prescriber reluctance, potential adverse regulatory action, and reputational and legal consequences. If you currently own SLNO and purchased prior to March 26, 2025 please contact Sophia Anne Silayan by email at [email protected] or call (833) 672-0814. Kuehn Law pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.